Got attention because:
24% gain intraday trading ->
Ticker details on google finance ->
Products from the company -> http://recropharma.com/?page_id=95
About the product -> http://en.wikipedia.org/wiki/Dexmedetomidine
Buy with short term goals. A good 5-10% growth in the run upto the first quarterly results should be a given seeing the volatility so far.
The sell Dexmedetomidine (http://en.wikipedia.org/wiki/Dexmedetomidine)
Dexmedetomidine is indicated for sedation of critically ill or injured
patients in an intensive care unit setting.
Its indication in the US was recently expanded to include nonintubated patient requiring sedation for surgery or procedures short-term. It is also useful as an adjunct for sedation and general anesthesia in the setting of certain operations and invasive medical procedures, such as colonoscopy. There are no absolute contraindications to the use of dexmedetomidine. Limiting its usefulness is the caution that the drug cannot be bolused due to concerns about peripheral Î±2-receptor stimulation with resulting hypotension and bradycardia, combined with its current high cost relative to generic medications such as propofol, fentanyl and midazolam which can achieve similar clinical effects.
The recent expansion of usage application and the relaxing of patent
rights in 2013 reducing costs puts Recro is a position for growth.
Also being a new company that's just gone IPO there's a lot that Recro would want to offer to get the attention of the market.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.